Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q1 2026 Earnings Presentation
9 slides from Phibro Animal Health's earnings presentation, Nov 6, 2025
Slide 1: Phibro Animal Health Corporation Webcast and Conference Call
Phibro Animal Health Corporation Webcast and Conference Call November 6, 2025 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2026 First Quarter Ended September 30, 2025 November 6, 2025 Webcast and Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or cur
Slide 3: Key Themes
Key Themes Strong Advances in Continued Sales FY2026 Full Year Performance in Companion Animal Momentum Guidance Animal Health Oral Care Q1 Total Consolidated sales and Q1 Total Animal Health sales Launch of Restoris™, a 2026 guidance adjusted EBITDA growth of 40% and adjusted EBITDA growth of break
Slide 4: Financial Performance - Consolidated
Financial Performance - Consolidated First Quarter, Year-on-Year comparison $ in millions, except per share data Q1 Q1 YOY FY25 FY26 %∆ Consolidated Net Sales $ 260.4 $ 363.9 40% Net Income $ 7.0 $ 26.5 NA Diluted EPS $ 0.17 $ 0.65 NA Adjusted EBITDA $ 30.7 $ 61.9 102% Adjusted Net Income $ 14.1 $ 2
Slide 5: Financial Performance – Animal Health
Financial Performance – Animal Health First Quarter, Year-on-Year comparison $ in millions Q1 Q1 FY26 YOY Q1 FY26 FY26 YOY FY25 Legacy %∆ New MFA Total %∆ Animal Health Net Sales $ 182.5 $ 203.0 11% $ 80.5 $ 283.5 55% MFAs & other 107.8 114.7 6% 80.5 195.2 81% Nutritional specialties 42.6 48.2 13% N
Slide 6: Financial Performance – Other Segments
Financial Performance – Other Segments First Quarter, Year-on-Year comparison $ in millions Q1 Q1 YOY FY25 FY26 %∆ Mineral Nutrition Net Sales $ 59.1 $ 63.0 7% Adj. EBITDA $ 3.8 $ 4.5 20% Adj. EBITDA Margin 6.4% 7.2% +80 bps Performance Products Net Sales $ 18.8 $ 17.4 (7%) Adj. EBITDA $ 2.3 $ 1.6 (
Slide 7: Key Capitalization Metrics
Key Capitalization Metrics September 30, 2025 Free cash flow was $34 million for the TTM -- positive cash from operating activities Free Cash Flow (1) of $77 million, less capital expenditures of $(43) million. Cash and cash equivalents of $85 million 3.3x gross leverage ratio; $749 million total de
Slide 8: Financial Guidance – Phibro
Financial Guidance – Phibro Fiscal Year 2026 $ in millions, except earnings per share (EPS) data FY 2025 FY 2026 FY 2026 Previous Updated Actual Low High Low High Consolidated Net Sales $ 1,296 $ 1,425 $ 1,475 $ 1,425 $ 1,475 Net Income $ 48 $ 73 $ 83 $ 75 $ 85 Diluted EPS $ 1.19 $ 1.79 $ 2.03 $ 1.8
Slide 9: PAHC Company Overview Q&A
PAHC Company Overview Q&A 9 November 8, 2025 Webcast and Conference Call